Emerging agents for boron neutron capture therapy: Biomolecular carriers paving the way for precision radiotherapy
Chang Chen, Maosong Yang, Jiheng Wang, Ling Zhang, Shaobo Huang, Xiao Xu, Yang Liu · 2026
Read Emerging agents for boron neutron capture therapy: Biomolecular carriers paving the way for precision radiotherapy by Chang Chen, Maosong Yang, Jiheng Wang, Ling Zhang, Shaobo Huang, Xiao Xu, Yang Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13292235.txt.
Description
Chang Chen and co-authors review biomolecular carriers for boron neutron capture therapy in a 2026 article. In this radiotherapy, boron loaded into tumors splits under neutron fire and kills cells from inside. The carrier decides whether enough boron reaches the tumor. The only approved carriers so far are biomolecular, led by boronophenylalanine, cleared in Japan. The review sorts carriers by their biological vehicle.
Amino acid carriers ride a transporter that hungry tumors overuse. Nucleoside prodrugs switch on inside dividing cells and lodge boron in DNA. Sugar-based carriers exploit glucose transporters, while peptides slip in through receptors or direct penetration. Liposomes gather in leaky tumors and can carry targeting decorations. Albumin systems draw rising attention for their safety and high boron loads. The stubborn challenge is sheer dose, since each cell needs vast boron numbers. Protein carriers may finally clear that bar.
Catalog record
| CREATOR | Chang Chen, Maosong Yang, Jiheng Wang, Ling Zhang, Shaobo Huang, Xiao Xu, Yang Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |